Affymetrix

AQTUAL NAMES GREGG C. FERGUS TO ITS BOARD OF DIRECTORS

Retrieved on: 
Tuesday, December 19, 2023

HAYWARD, Calif., Dec. 19, 2023 /PRNewswire/ -- Aqtual, a precision medicine company with a novel cfDNA platform to aid in treatment decisions for chronic diseases and cancers through a simple blood test, announced today that Gregg C. Fergus has joined as a member of its board of directors.

Key Points: 
  • Gregg brings over 30 years of corporate, entrepreneurial, and venture capital experience working with category-defining companies in life sciences.
  • Gregg was CEO of 4Catalyzer, where he launched groundbreaking companies, including Butterfly Network, Hyperfine, Quantum-Si, and AI Therapeutics.
  • Prior to 4Catalyzer, Gregg was president and COO of Ion Torrent, which sold to Life Technologies and is now a division of Thermo Scientific.
  • Gregg currently serves as executive chairman of the board at Ascertain.

Velo3D Announces Leadership Transition and Commencement of Strategic Business Review

Retrieved on: 
Friday, December 15, 2023

Additionally, the Board of Directors has commenced a strategic business review process to explore alternatives in order to maximize shareholder value.

Key Points: 
  • Additionally, the Board of Directors has commenced a strategic business review process to explore alternatives in order to maximize shareholder value.
  • Potential strategic alternatives to be explored or evaluated may include, but are not limited to, a strategic transaction, potential merger, business combination or sale.
  • There can be no assurance that the Company’s strategic review process will result in any transaction or other strategic outcome.
  • Velo3D does not intend to disclose further developments on this strategic review process unless and until it determines that such disclosure is appropriate or necessary.

BIO-TECHNE APPOINTS KIM KELDERMAN AS CHIEF EXECUTIVE OFFICER

Retrieved on: 
Thursday, October 19, 2023

MINNEAPOLIS, Oct. 19, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Board of Directors appointed Kim Kelderman as President and Chief Executive Officer effective February 1, 2024.

Key Points: 
  • MINNEAPOLIS, Oct. 19, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Board of Directors appointed Kim Kelderman as President and Chief Executive Officer effective February 1, 2024.
  • Prior to assuming CEO responsibilities, Mr. Kelderman will become Chief Operating Officer (COO) effective November 1, 2023, where he will be responsible for the day-to-day operations of the Company.
  • Mr. Kelderman succeeds Chuck Kummeth, who will be retiring from the company after serving as President, Chief Executive Officer and Board Director for the past 10 years.
  • "Kim is the ideal candidate to lead Bio-Techne during the Company's next stage of growth," said Chuck Kummeth, Bio-Techne's President and Chief Executive Officer.

Vilya Appoints Cyrus Harmon, Ph.D., as Chief Executive Officer

Retrieved on: 
Tuesday, October 17, 2023

VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, today announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer.

Key Points: 
  • VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, today announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer.
  • “I am very excited to join the phenomenal team at Vilya developing new macrocycle drugs,” said Harmon.
  • Previously, Harmon co-founded and served as CEO of Olema Oncology, a company focused on women’s cancers, before transitioning to the role of Chief Research Officer.
  • Harmon joins Katerina Leftheris, Ph.D., Vilya’s Chief Scientific Officer on the company’s leadership team.

Element Biosciences Adds Genomics Executive to Leadership Team to Accelerate Corporate Development

Retrieved on: 
Thursday, August 24, 2023

SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the appointment of veteran life science executive Yaron Hakak as Senior Vice President of Corporate and Business Development.

Key Points: 
  • As Element grows its commercial organization, Yaron will lead business and corporate development to accelerate the company's global growth through high impact business and strategic partnerships, joint ventures, and acquisitions.
  • "I'm thrilled to welcome Yaron to Element as we continue to expand around the world with tools to advance scientific discoveries," said Molly He, Ph.D., CEO and Co-Founder of Element Biosciences.
  • Before that, he served as Director of Business Development at Affymetrix, where he supported corporate activities related to its genomics and proteomic product portfolios.
  • "I am honored to join the Element team to help further the development and worldwide adoption of the AVITI sequencing platform," said Yaron Hakak.

Bloom Science Names Top Biotechnology Executive, Dr. Grace E. Colón, Board Chair

Retrieved on: 
Wednesday, May 17, 2023

Dr. Colón has over 25 years of experience in biopharma, genomics, diagnostics, healthcare, industrial microbiology/biotechnology, synthetic biology, venture capital, management consulting, and entrepreneurship.

Key Points: 
  • Dr. Colón has over 25 years of experience in biopharma, genomics, diagnostics, healthcare, industrial microbiology/biotechnology, synthetic biology, venture capital, management consulting, and entrepreneurship.
  • She serves on the boards of CareDx, Voyager Therapeutics, the MIT Corporation (MIT's Board of Trustees) and the Biotechnology Innovation Organization (BIO), and is also Executive Chair (formerly CEO) of ProterixBio.
  • "We are thrilled to welcome Dr. Colón as the Chair of our Board of Directors," said Christopher Reyes, PhD, founder and CEO of Bloom Science.
  • "Bloom Science is the leading microbiome company dedicated to developing innovative therapies for neurological diseases through the gut-brain connection," said Dr. Colón.

Adela Announces Appointment of Alan Williams as Chief Operating Officer

Retrieved on: 
Thursday, May 11, 2023

FOSTER CITY, Calif., May 11, 2023 /PRNewswire/ -- Adela, Inc., an innovator in minimal residual disease (MRD) detection and monitoring and early cancer detection with a routine blood test, announced today that Alan Williams, PhD has joined the company as Chief Operating Officer. Alan brings proven and deep expertise in product development, and in scaling clinical laboratory operations from his senior executive roles at Somalogic, Thermo Fisher Scientific (Ion Torrent), and Affymetrix.

Key Points: 
  • "I am thrilled to have joined the exceptionally innovative and talented team at Adela," said Alan Williams, Chief Operating Officer at Adela.
  • Adela has the opportunity to improve the care for the millions of people impacted by cancer."
  • "I am delighted to welcome Alan to Adela.
  • "Alan's leadership will help Adela accelerate bringing our products to market, leveraging the unique advantages of Adela's genome-wide methylation platform."

Arima Genomics Announces Appointment of Veteran Genomics Leader Gabrielle Raia as Senior Vice President of Sales

Retrieved on: 
Monday, May 1, 2023

Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve human health, today announced the appointment of Gabrielle ‘Gabi’ Raia to the newly created position of Senior Vice President of Discovery and Clinical Sales.

Key Points: 
  • Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve human health, today announced the appointment of Gabrielle ‘Gabi’ Raia to the newly created position of Senior Vice President of Discovery and Clinical Sales.
  • “Knowledge of the spatial organization of DNA within cells unravels powerful use cases for scientific and translational research, but until recently, this technology was only accessible to specialized laboratories with sophisticated bioinformatics capabilities,” said Gabi Raia, Senior Vice President, Discovery and Clinical Sales at Arima Genomics.
  • Most recently, she was Senior Vice President, Global Sales for Genapsys and Sequencing Health, responsible for strategic market assessment, global launch planning, and scaling the sales organization.
  • Gabi previously held senior sales leadership roles with Invitae following their acquisition of ArcherDX, Illumina, Life Technologies, PacBio, and Affymetrix.

Acuamark Diagnostics Welcomes Giulia Kennedy, Former Chief Scientific and Chief Medical Officer of Veracyte, to its Board of Directors

Retrieved on: 
Wednesday, April 26, 2023

Acuamark Diagnostics has appointed Giulia Kennedy, Ph.D. , formerly global chief scientific officer and chief medical officer of diagnostics company Veracyte , to its board of directors.

Key Points: 
  • Acuamark Diagnostics has appointed Giulia Kennedy, Ph.D. , formerly global chief scientific officer and chief medical officer of diagnostics company Veracyte , to its board of directors.
  • She most recently served as global chief scientific officer and chief medical officer at Veracyte, a cancer genetics company focused on treatment planning and prognostics in various cancers.
  • Prior to joining Veracyte, Dr. Kennedy was at Affymetrix, where she accelerated commercialization of the company’s platform into multiple emerging markets.
  • I’m very pleased to join the Acuamark Board of Directors and to bring my expertise in company building and in development and commercialization of diagnostics products to bear on further advancing the company.”
    “Dr.

GeneCentric Therapeutics Appoints Brian Kelly as SVP Business Development

Retrieved on: 
Wednesday, April 12, 2023

GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Brian Kelly as Senior Vice President of Business Development.

Key Points: 
  • GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Brian Kelly as Senior Vice President of Business Development.
  • Mr. Kelly will be responsible for spearheading the Company’s global business growth strategy, with a focus on diagnostic partnering and biopharmaceutical alliance programs and other corporate development initiatives to advance the Company’s strategic priorities.
  • A business leader in cancer research and genomic analysis technologies, Mr. Kelly has more than 15 years’ experience in global business and market development, companion diagnostics and biomarker strategies.
  • Prior to that, he held various clinical market development and commercial roles at Life Technologies, Pacific Biosciences and Affymetrix.